Giridhar Tirucherai - Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb Company

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 65 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Manal F. Abdelmalek,Arun J. Sanyal,Atsushi Nakajima,Brent A. Neuschwander-Tetri,Zachary D. Goodman,Eric J. Lawitz,Stephen A. Harrison,Ira M. Jacobson,Kento Imajo,Nadege Gunn,Dina Halegoua-DeMarzio,Takemi Akahane,

CLINICAL GASTROENTEROLOGY AND HEPATOLOGYno. 1 (2024)

Cited0Views0Bibtex

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Rohit Loomba,Arun J. Sanyal,Atsushi Nakajima,Brent A. Neuschwander-Tetri,Zachary D. Goodman,Stephen A. Harrison,Eric J. Lawitz,Nadege Gunn,Kento Imajo,Natarajan Ravendhran,Takemi Akahane,Bradly Boone,

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associationno. 1 (2024): 102-112.e9

Cited5Views0WOSBibtex

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Ga...（2024）

Cited4Views0WOSBibtex

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY（2024）

Cited0Views0Bibtex

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy

Francesco Muntoni,Barry J. Byrne,Hugh J. McMillan,Monique M. Ryan,Brenda L. Wong,Juergen Dukart, Amita Bansal,Valerie Cosson, Roxana Dreghici,Maitea Guridi,Michael Rabbia,Hannah Staunton,

Neurology and Therapyno. 1 (2024): 183-219

Cited0Views0WOSBibtex

Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment

Hisham Qosa, Claudia H M C de Oliveira,Giovanni Cizza,Eric J Lawitz, Nicholas Colletti, Jeffrey Wetherington,Edgar D Charles,Giridhar S Tirucherai

Clinical and translational scienceno. 10 (2023): 1791-1802

Cited1Views0WOSBibtex

Reinitiation of Ozanimod After Dose Interruption: Assessment of Effect on Heart Rate

Peijin Zhang,Mary Syto, Susan Walker,Giridhar Tirucherai, Bindu Murthy, Daniel Tatosian

The American Journal of Gastroenterologyno. 10 (2023): S843-S843

Cited0Views0Bibtex

BMS-986278, an Oral Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, for Patients With Idiopathic Pulmonary Fibrosis: Results From a Phase 2 Randomized Trial

T. J. Corte,V. Cottin,M. K. Glassberg,M. Kreuter,T. Ogura, T. Suda,J. G. Goldin, E. Berkowitz,B. Elpers, S. Kim,G. S. Tirucherai, H. Watanabe,

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Cited0Views0Bibtex

Case study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples

Hong Shen,Jinping Gan,Giridhar Tirucherai

Elsevier eBookspp.189-199, (2023)

Cited0Views0Bibtex

Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod

Peijin Zhang, Fareeda Hosein, Kyungha Yu, Susan Walker,Mary Syto,Giridhar Tirucherai, Bindu Murthy, Daniel Tatosian

The American Journal of Gastroenterologyno. 10 (2023): 976-976

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn